Nurix Therapeutics Under Pressure After Earnings

Nurix Therapeutics reported a disappointing first quarter of 2026, with revenue falling sharply and net loss widening. The end of the initial contribution from its partnership with Sanofi weighed on sales, while higher R&D spending reflects progress in its pipeline, particularly in hematology and in candidates from its protein degradation platform. Despite the tougher operating backdrop, Wells Fargo only cut its price target to $28 while maintaining a positive rating, and analysts remain broadly confident in the stock's rebound potential. In the near term, however, visibility remains limited and the shares may stay volatile until the company shows a tangible improvement in revenue.